Optimizing Treatment for Patients with CLL - Baseline Assessment

The following questions are designed to assess your knowledge and practice of patients with relapsed/refractory CLL/SLL.

Cole Sterling, MD

Assistant Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference.

Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty.

As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation.

Stephan Stilgenbauer, MD

Professor of Medicine and Medical Director, 
Head Early Clinical Trials Unit (ECTU), CCCU
Head Division of CLL Department of Internal Medicine III
Comprehensive Cancer Center Ulm
Ulm, Germany

Dr. Stephan Stilgenbauer is Professor in the Department of Hematology, Oncology, Rheumatology and Infectious Diseases at the University of Ulm, Germany. He received his medical training at Ruprecht-Karls Universität Heidelberg Medical School, Germany with electives in Hamilton, Canada; Jerusalem, Israel; Bath, UK and Cambridge, UK. He went on to complete his final year at the Baylor College of Medicine and MD Anderson Cancer Center in Houston, Texas. His research is focused on the investigation of molecular factors in pathogenesis, and prognosis of CLL and other lymphomas as well as the development of novel treatment approaches for these diseases. Dr. Stilgenbauer has authored or co-authored numerous original articles, reviews and book chapters in journals such as the New England Journal of Medicine, Lancet, Nature, Nature Medicine, Journal of Clinical Oncology, Blood, Leukemia, Oncogene, and Haematologica.
Incorporate the latest guideline recommendations and clinical evidence for the use of targeted therapies in CLL/SLL, including relapsed/refractory (R/R) CLL/SLL.
Integrate new data on emerging treatments into CLL/SLL treatment algorithms.
Employ available evidence and expert guidance in approaches for optimizing therapy sequencing across different lines of treatment in CLL/SLL.